Zobrazeno 1 - 10
of 154
pro vyhledávání: '"Alfred, Hobisch"'
Autor:
Zoran Culig, Lukas Kenner, Alfred Hobisch, Jeffrey A. Nemeth, Martin Susani, Hannes Neuwirt, Frédéric R. Santer, Martin Puhr
Supplementary Figure 2 from Down-regulation of Suppressor of Cytokine Signaling-3 Causes Prostate Cancer Cell Death through Activation of the Extrinsic and Intrinsic Apoptosis Pathways
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02b4547a9b02ab49bc1bd8a19a90dccc
https://doi.org/10.1158/0008-5472.22378254
https://doi.org/10.1158/0008-5472.22378254
Autor:
Zoran Culig, Lukas Kenner, Alfred Hobisch, Jeffrey A. Nemeth, Martin Susani, Hannes Neuwirt, Frédéric R. Santer, Martin Puhr
Supplementary Figure 1 from Down-regulation of Suppressor of Cytokine Signaling-3 Causes Prostate Cancer Cell Death through Activation of the Extrinsic and Intrinsic Apoptosis Pathways
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d12ff31b48886cf743a3bb174d78298
https://doi.org/10.1158/0008-5472.22378257
https://doi.org/10.1158/0008-5472.22378257
Publikováno v:
International Brazilian Journal of Urology, Vol 37, Iss 4, Pp 488-494 (2011)
PURPOSE: To evaluate the clinical outcome after placement of AdVance® sling in men with stress urinary incontinence after prostate surgery. MATERIALS AND METHODS: Incontinence was assessed on basis of number of pad usage. Patients' satisfaction was
Externí odkaz:
https://doaj.org/article/b1a2bfb6006d40cf86e85656b2606568
Autor:
Friedrich Aigner, Karl Scheiber, Alfred Hobisch, Florian Zangerl, Stefania Pilloni, Andreas P. Berger, Andreas Fritzer, Patrick Rein, Brigitte Stoehr, Hannes Steiner, Josef Aufderklamm
Publikováno v:
BJU International. 107:1074-1079
Study Type – Therapy (prospective cohort) Level of Evidence 2a What’s known on the subject? and What does the study add? The debate concerning standard treatment following unilateral inguinal orchiectomy for patients with clinical stage I seminom
Publikováno v:
Endocrine-Related Cancer. 17:525-538
Fibroblast growth factor-2 (FGF-2) is highly expressed in prostate cancer. It promotes tumour progression through multiple pathways including those of signal transducers and activators of transcription factor 3 (STAT3), mitogen-activated protein kina
Autor:
Alfred Hobisch, Isabella-Carolina Marei, Eleonore Fink, Hans-Jörg Neumann, Michael Rauchenwald, Gero Kramer, Walter Stackl, Michael Krainer, Nikolaus Schmeller, Maria De Santis, Andreas Reissigl, Wolfgang Höltl
Publikováno v:
Wiener klinische Wochenschrift. 120:440-449
Fur viele Jahre glaubte man, der Nutzen einer Chemotherapie beim Prostatakarzinom sei auf die Palliation der Erkrankung in spaten Stadien beschrankt, und so wurde diese Behandlungsoption den Patienten – wenn uberhaupt – nur am Ende des Krankheits
Autor:
Zoran Culig, Alfred Hobisch
Publikováno v:
Therapy. 5:47-56
Androgen ablation is the mainstay treatment for non-organ-confined prostate cancer. This treatment is only palliative and patients may present with disease progression because of changes in androgen signaling and other pathways. The androgen receptor
Autor:
Thomas J. Sebo, Kristin A. Raclaw, Jose D. Debes, Alfred Hobisch, Hannelore V. Heemers, Donald J. Tindall, Kevin M. Regan, Linda M. Murphy, Zoran Culig
Publikováno v:
Cancer Research. 67:3422-3430
Standard therapy for nonorgan confined prostate cancer aims to block the production or action of androgens. Although initially successful, antiandrogen therapy eventually fails and androgen depletion independent (ADI) disease emerges. Remarkably, ADI
Autor:
Anton Hittmair, J. Eberle, Marcus V. Cronauer, Alfred Hobisch, Andreas Reissigl, Georg Bartsch, Christian Radmayr, Zoran Culig, B. Andrew C. Cato, Helmut Klocker, F. Kaspar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e6f5065e4c60a07a9ca159091f4b947
https://doi.org/10.1159/000424535
https://doi.org/10.1159/000424535
Autor:
Hannes Steiner, Alfred Hobisch, Jeffrey A. Nemeth, Zoran Culig, Hermann Dietrich, Patrizia Moser, Marian T. Nakada, Ilaria T. Cavarretta, Mohamed H. Zaki, Jasmin Bektic, Andreas P. Berger
Publikováno v:
The Prostate. 66:1744-1752
BACKGROUND Interleukin-6 (IL-6) is a multifunctional regulator of cellular events in prostate cancer. LNCaP-IL-6+ cells selected in the presence of IL-6 were taken for assessment of effects of the chimeric monoclonal anti-IL-6 antibody CNTO 328. METH